BOOK EARLY TO SAVE $100

June 18-20 | Shanghai, China
www.cartcr-asia.com

CAR-TCR Summit Asia

Engineering a Cancer-Free World



Dedicated to creating safer, more effective and globally commercial CAR-T and TCR therapies for patients in need

Expert Speakers include:

Richard Wang
CEO
Fosun Kite

James Li
CEO
JW Therapeutics

Ting He
CEO
Immunochina Pharmaceuticals

Frank Fan
CSO
Nanjing Legend Biotechnology

Cheng Liu
CEO
Eureka Therapeutics

Lead Partner

MACS Miltenyi Biotec

Tel: +44 (0)20 3141 8700 **Email:** info@hansonwade.com
www.cartcr-asia.com Cell Immunotherapy @CAR_TCell

hansonwade

Welcome to the Annual CAR-TCR Summit Asia

China currently runs more clinical trials than Europe and the US combined, leading the way in the development of CAR-T and TCR therapies. Boasting one of the largest economies in the world, commercial success within this market provides a **significant opportunity for the global distribution of CAR-TCR Therapies.**

As the **race to globalise** CAR-TCR Therapies continues, the ***CAR-TCR Summit Asia*** explores the next generation candidates that have **improved efficacy in solid tumor** indications such as gastric and colorectal cancers.

Join experts from Fosun Kite, JW Therapeutics, Legend Biotech, GSK, Unicar-Therapy and many more to understand how we can **effectively manipulate the immunosuppressive tumor microenvironment** to ensure effective trafficking and homing of CAR-TCR cells in solid tumor indications.

Explore novel updates on the hotly anticipated work taking place to **progress allogeneic cell therapies** for improved commercial returns. **Streamline your manufacturing and logistics** supply chain to ensure **effective global distribution** of your CAR-TCR therapy product.

Join us and over 100 of the world's leading experts as we work to **deliver safe, effective and commercially viable global distribution** of novel and innovative CAR-TCR products.

Shaksita Desai
Portfolio Director

Hear what previous attendees have to say

"The CAR-TCR Summit is the go to meeting for researchers in this field"

Director of Research,
TC BioPharm

"This conferences continues to bring together thought leaders, with real world experiences who are willing to share their learnings to continue to accelerate and advance the field for patients"

Innovation Leader - Cell & Gene Therapy Technology,
GE Healthcare

Navigate the Clinical and Commercial Pathways to bring to market CAR and TCR Therapies:



Solid Tumors:
Optimize CAR-T therapies with enhanced synthetic and genetic engineering



Allogeneic:
Overcome safety and efficacy issues faced with allogeneic therapies

Quality:
Assess the efficiency of manufacturing processes through improved quality assurance measures

Regulations:
Understand the complexities of global regulations from IND submission through to approval

Commercialization:
Meet the growing needs of the patient market through increasing the affordability and accessibility of CAR-TCR Therapies

Why experts attend the CAR-TCR Summits?

"Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring, and the CAR-TCR Summit [in Boston] is no different. We are energized by the discussions about CAR-TCR and its potential applications for bringing new therapies to patients in need"

NOVARTIS

"CAR-TCR Summit is a content-packed conference in 2 days filled with some of the most innovative and inspirational work in the regen med field today. Great event to improve networking and make meaningful contacts"

AKRONBIOTECH

"This is a best in class and top summit in the CART TCR area which is an invaluable asset to both industries and academia"

Penn
University of Pennsylvania

"A nice blend of academic, biotech, and pharmaceutical attendance in an environment that encourages cross-fertilization of ideas within CAR-T therapy"

C4 Therapeutics

"This meeting enables us to see what is happening and discuss real world applications. It is extremely informative to consider what to do when we apply CAR or TCR to patients in Japan"

TaKaRa

"The CAR-TCR Summit [in Boston] provided a great opportunity to rapidly learn about the many advances in CAR-T and TCR technology. The meeting attracted high level representatives from development, manufacturing and commercialization from the key players in the industry and provided excellent networking opportunities"

Georgia Tech

"As a newcomer to the CAR-T space, I felt this meeting to be extremely valuable as it provided me the opportunity to meet many of the movers and shakers in the space. Great education and information!"

AURORA BIOPHARMA

"I can't speak highly enough about this conference. This conference allowed me to keep informed of the latest research and development on T cell therapies. I was also able to network with some of the leaders in T cell immunotherapies from both academia and the industry"

Memorial Sloan Kettering Cancer Center

"It was a great opportunity to learn and exchange ideas with outstanding scientists and solution providers how to provide curative therapy for patients with cancer in Asia and beyond"

Daiichi-Sankyo

"This meeting provides ample opportunities to network with key players in CAR-TCR therapy of Asia. It provides the most forefront information from the clinics. The partners in the meeting bring cutting-edge technology developed to solve problems surrounding manufacturing CAR-TCR T cells, which are critical for this area"

NUS

"Very interesting presentations with an agenda and topics being current. The conference has been well organized and perfectly timed"

ICON
A Symbol of Excellence

"Great place to meet Asia's Cell & Gene Therapies leaders"

MARKEN
a UPS Company

"This Conference gathered many experts from biopharmaceutical industry to explore the current trends in T cell therapy, and to share cutting edge studies in advancing cell therapies into the clinic"

Singapore Immunology Network
A*STAR

"A great opportunity to connect with some of the best experts in the field"

Your Expert Speakers

Yu Zhang
Co-Founder & CEO
Aeon Therapeutics

Zhongwei Xu
CSO
Bioceltech Therapeutics

Shawn Foley
Attorney, Intellectual Property
Burns & Levinson LLP

Zonghai Li
CEO & CSO
CARsgen Therapeutics

Tony Liu
CEO
Cellular Biomedicine Group

Lucas Chan
Co-founder & CSO
CellVec

Mark Sawicki
CCO
Cryoport

Yanni Lin
CTO & Co-founder
Cure Genetics

Cheng Liu
CEO
Eureka Therapeutics

Richard Wang
CEO
Fosun Kite

Cedrik Britten
VP & Head, Oncology Cell Therapies Unit
GSK

Daniel Song
Deputy General Manager
Hrain Bioechnology

Martin Lachs
VP, Global Project Meeting
ICON

Ting He
CEO
Immunochina Pharmaceuticals

Zhao Wu
CSO
Innovative Cellular Therapeutics

James Li
CEO
JW Therapeutics

Paul Dai
CEO
Kaedi

Thomas Fellner
Head, BD & Account Manager, Cell & Gene Technologies
Lonza Pharma & Biotech

Peter Hoang
CEO
Marker Therapeutics

Hermann Bohnenkamp
VP, Business Development APAC
Miltenyi Biotec

Frank Fan
CSO
Nanjing Legend Biotechnology

Erin Piazza
Bioinformatics Scientist
NanoString Technologies

Lin Yang
CEO
Persongen

Bing Wang
CEO
Refuge Biotechnologies

Mark Aspinall O'Dea
EMEA Business Development Manager
Retrogenix

Yu Lei
CEO
Shanghai Unicar-Therapy Bio-medicine Technology Co

Mingjun Wang
Vice President
Shenzhen Innovation Immunotechnology

Jishuai Zhang
CSO
Shenzhen Pregene Biopharma

Greg Motz
Director, Immunopharmacology
Unum Therapeutics

Yi Li
CSO
XLifeSci

Conference Day One
Wednesday 19th June 2019

8.00 Coffee & Registration

9.00 Chair's Opening Remarks

9.15 CEO Leaders Panel

With CAR-T therapies now on the market and spreading globally for approval, what does the future hold and what are the next steps to ensure these, and future adoptive immunotherapies reach all patients in need? Spend an hour with this unique panel of CEOs and company executives from leading CAR-TCR developers to better understand strategic challenges and future priorities for the next generation CAR-T and TCR cell therapy development.

Zonghai Li
CEO & CSO
CARsgen Therapeutics

Tony Liu
CEO
Cellular Biomedicine Group

Cheng Liu
CEO
Eureka Therapeutics

Richard Wang
CEO
Fosun Kite

Ting He
CEO
Immunochina Pharmaceuticals

James Li
CEO
JW Therapeutics

Hermann Bohnenkamp
VP, Business Development APAC
Miltenyi Biotec

10.15 Towards Commercialization: Accomplish the Challenges of Autologous Cell and Gene Therapies

- Control strategies for cell and gene therapies
- Considerations of a fully automated cell manufacturing process
- Process transfer and decentralized manufacturing strategies of CAR T cells

10.45 Morning Refreshments & Networking

Mark Sawicki
Chief Commercial Officer
Cryoport

11.45 Chain of Compliance™: The Standardization of Precision Medicine Logistics

- Increasing regulatory requirements supporting precision medicine distribution are emerging
- Chain of Compliance™ adherence will be a basic requirement for managing distribution
- How does this standardization impact clinical and commercial logistics strategies

Richard Wang
CEO
Fosun Kite

12.15 Bringing Yescarta® to China

Cheng Liu
CEO
Eureka Therapeutics

12.45 Towards Safer, Effective and Persistent T-Cell Therapies: Development of Antibody-TCR (AbTCR) Expressing T Cells Against Solid and Hematological Malignancies

- Addressing major barriers of current CAR-T: CRS and neurotoxicity risks
- Presenting our solution: ARTEMIS AbTCR T-cell Receptor Platform
- Safety validation of ARTEMIS platform in CD19+ NHL
- Understanding how Eureka built a versatile structure to go after both hem and solid tumor with ARTEMIS Plus
- Safety and efficacy validation in AFP+ HCC and CD19 programs are achieved
- Exploring future directions

1.15 Lunch & Networking

Research & Development

2.45 Selection of an Optimal Antibody as the Targeting Moiety of CAR-T Cells

- Immunogenicity of the antibody in the CAR-T cells
- Specificity of the antibody in the CAR-T cells
- Tonic signaling related to the antibody structure

Zonghai Li, CEO & CSO, **CARsgen Therapeutics**

3.15 TCR-T Cell-based Immunotherapy for Solid Cancers

- Analyzing recent advances in clinical trials using TCR-T cells
- Overcoming challenges in TCR-T cell-based cancer immunotherapy
- Exploring future directions and focuses including neoantigen based therapies

Mingjun Wang, Vice President, **Shenzhen Innovation Immunotechnology**

Manufacturing & Commercialization

2.45 Developing and Commercializing of CAR-T/TCR-T Product for Solid Tumors Using Automatic Manufacturing Process

- Comparison of CQA&CPP between CAR-T/TCR-T products for hematological and solid tumors
- Differences between using manual and automatic process during CAR-T/TCR-T products manufacture for solid tumors
- Developing a CAR-T/TCR-T product by using close, automatic manufacturing system
- Key considerations of setting down business model to commercialize CAR-T/TCR-T products manufacture for solid tumors in China: CMC, logistics, price and reimbursement

Yu Zhang, Co-Founder & CEO, **Aeon Therapeutics**

3.15 Approaches to Address the Challenges for Drug Commercialization for Cell and Gene Therapies; Particularly in China

- What China can bring to advancing the manufacture process in novel therapy modalities
- Manufacturing capabilities: addressing the "Achilles heel" of cell therapy
- The importance of strategic collaborations to improve manufacturing

Tony Liu, CEO, **Cellular Biomedicine Group**

3.45 Afternoon Refreshments & Poster Session

Research & Development

4.45 A Step Toward Standardization with the nCounter® CAR-T Characterization Panel

- NanoString has partnered with 8 leading CAR-T development centers to produce a new gene expression panel for the molecular characterization of CAR-T cells
- Using a 780-gene expression panel measuring T-cell activation, metabolism, exhaustion, and TCR receptor diversity with optional customization for measuring transgene expression
- Leveraging the robustness, ease of workflow and rapid time to results of the nCounter® platform, NanoString aims to provide a standardized set of biomarker discovery tools to both enable and advance the field

Erin Piazza, Bioinformatics Scientist, **NanoString Technologies**

Manufacturing & Commercialization

4.45 Viral Vector Engineering Approaches and Technologies

- Learn about quality control and replication competent Retrovirus/Lentivirus Testing
- Follow up and monitoring of patients for RCR/RCL testing
- Ensuring quality assurance of viral vectors
- Understanding the ability and kinetics of potential RCR/RCL
- Replication in cellular products

Yu Lei, CEO, **Shanghai Unicar-Therapy Bio-medicine Technology Co**

Mark Aspinall O'Dea EMEA Business Development Manager **Retrogenix**	5.15	**Screening CAR T Cells for Target Specificity Using Human Cell Microarray Technology** • Optimisation of the human cell microarray technology for off-target screening of whole engineered CAR T cells, in addition to antibodies and ScFvs • An efficient approach for specificity screening of novel cell therapies to support safety assessment and provide key data prior to IND submissions
Frank Fan CSO **Nanjing Legend Biotechnology**	5.45	**Competition and Challenges in the Space of BCMA Targeted Immunotherapy** • Overview of clinical stage immunotherapies targeting BCMA • Evaluating the advantages and disadvantages of autologous BCMA-CAR-T technology in development • Discussing challenges encountered and potential solutions

6.15 **Chairman's Closing Remarks**

6.30 **CAR-TCR Drinks Reception**

7.30 **Close of Day 1**

"This meeting enables us to see what is happening and discuss real world applications. It is extremely informative to consider what to do when we apply CAR or TCR to patients in Japan"

Takara Bio

"An excellent event in which key industry drivers share and exchange knowledge for the benefit of the industry as a whole"

Xcell Biosciences

Conference Day Two
Thursday 20th June, 2019

8.00 **Breakfast & Networking**

9.00 **Chair's Opening Remarks**

Thomas Fellner
Head, BD & Account Manager, Cell & Gene Technologies
Lonza Pharma & Biotech

9.15 **Entering A New Era of Cell and Gene Therapies: Industrialization of Manufacturing**

9.45 **Morning Refreshments & Networking**

Research & Development

11.15 Progress in a First-in-Class Dominant Negative PD-1 Armored CAR-T in Clinical Trials

- First-in-class dnPD1 armored anti-CD19 CAR+ –T Cell the theory and the difference compared to traditional CAR-T cells
- Discuss the therapeutic effect and results
- Evaluate clinical research progress with achievements
- International registration progress

Zhao Wu, CSO, **Innovative Cellular Therapeutics**

11.45 Key Considerations for Transitioning a Cell Therapy from Early Development into a Global Late-Phase Development for Registration

- Discussing standard vs accelerated development
- Cross-functional alignment
- Trade-offs between speed and opportunity

Cedrik Britten, VP & Head, Oncology Cell Therapies Unit, **GSK**

12.15 Treatment of Relapse or Refractory non-Hodgkin Lymphoma by CD19 Targeted Chimeric Antigen Receptor T Cells

- CD28 and 41BB co-stimulatory domains were compared in a double arm randomized clinical study
- Single treatment of CAR-T lead to continuous response
- CAR-T cells could persist in peripheral blood for months after infusion

Ting He, CEO, **Immunochina Pharmaceuticals**

Manufacturing & Commercialization

11.15 Manufacturing Development of an Off-the-Shelf, Allogeneic CAR-T Platform

- Application of gene editing in adoptive cell therapy
- Harnessing the power of genome editing and immune regulation to develop the next-generation allogeneic CAR-T therapy
- Off-the-shelf CAR-T product development from bench to bedside: manufacturing and commercialization
- Perspective on the future of CAR-T therapy manufacture

Yanni Lin, CTO & Co-founder, **Cure Genetics**

11.45 GMP Manufacturing of Lentiviral Vectors For Clinical Applications

- Lentiviral Vectors provides a critical pathway in enabling safe and efficacious genetic modification of target cells both in vivo and ex vivo
- Lentiviral Vectors has a substantial clinical safety profile as well as advanced QC analytics to support its release as a product for clinical applications
- Lentiviral Vectors is a critical component in CAR-T manufacture including the recently approved Kymriah CAR-T cellular therapy for ALL and DLBCL indications
- Availability of GMP grade Lentiviral Vectors is currently a worldwide constraint in enabling the manufacture of clinical cellular therapy products
- Manufacture of Lentiviral Vectors is a complex process due to its instability and toxicity to producer cells, which makes it a challenge to produce compliant and high yield product
- Developers are focusing on innovative solutions to tackle these challenges in order to improve yields and accessibility of this critical product

Lucas Chan, Co-founder & CSO, **CellVec**

12.15 Roundtable Discussion: Logistics and Distribution of CAR-T Cells Domestically

- Operationalizing an efficient supply chain to meet patient demand
- Integrating the sourcing chain into your scale up strategy
- How do you secure the supply chain to ensure you have the capability for scale up?
- Operating across different supply chain models
- Overcoming logistics challenges across many sites

12.45 Lunch & Networking

Research & Development

1.45 Develop an Efficient CAR-T for Solid Tumor therapy by Synthetic Biology

- CAR T-cell therapy for solid tumors: novel strategies, immunological principles and drawbacks of current genetic engineering platform
- State of art design efficient CAR molecules by synthetic biology technology
- Design and optimize CAR molecules for solid tumors
- Evaluate the case study of KD-025 CAR-T in hepatocellular carcinoma and glioblastoma
- Combining synthetic biology and immunology: hacking CARs to expand their therapeutic capabilities

Paul Dai, CEO, **Kaedi**

2.15 Dynamic Regulation of Multiple Genes in Adoptive Cell Therapies

- Contextual regulation of gene expression using CRISPR interference and activation
- Integrating multiple checkpoint inhibitor biology into a single therapeutic cell
- Programming T-cells for survival, proliferation and cytotoxicity in the tumor microenvironment

Bing Wang, CEO, **Refuge Biotechnologies**

2.45 ACTR and BOXR: Addressing the Challenges of T-Cell Therapies in Solid Tumors

- Key challenges facing T-cell therapy in solid tumors include on-target/off-tumor toxicity and immunosuppression in the tumor microenvironment. Unum has developed two novel T cell technologies to address these challenges
- The ACTR T-cell platform allows for selective tumor antigen targeting, efficiently killing tumor cells with high antigen expression while sparing normal tissues with low antigen expression
- The BOXR T-cell platform enables engineered T-cells to overcome specific mechanisms of TME immunosuppression that include metabolic competition, immunosuppressive cell types (Treg, MDSC), and exhaustion due to chronic stimulation

Greg Motz, Director, Immunopharmacology, **Unum Therapeutics**

Manufacturing & Commercialization

1.45 Automated Manufacturing of Chimeric Antigen Receptor T Cells

- Reduce the risk of contamination and production failure
- Analyze the development trends
- Applying an automated platform to CAR-T cell manufacturing for industrialization and clinical success

Lin Yang, CEO, **Persongen**

2.15 CAR T: A Chronological Survey; From Whence it Came and Opportunities for Future Patenting

- Early generations of CAR-T patents and their relevance to FDA – approved CAR-T products
- Alternative strategies for patenting your CAR-T invention
- Patentability vs. Commercialization of your CAR-T product

Shawn Foley, Attorney, Intellectual Property, **Burns & Levinson LLP**

2.45 Roundtable Discussion: Business Aspects of Engineered T Cell Therapies

- Ensuring the commercial viability of products
- Mergers and acquisitions
- Partnering and licensing
- Encouraging collaboration in the space
- Overcoming IP challenges to enhance forward movement in the field

2.45 Afternoon Refreshments & Networking

3.45 Keynote: Putting the Patients First

- What access to this kind of medicine means on the patient level
- Health insurance and how they do or do not cover payment for cancer treatments
- Patient frustration in accessing vital treatments
- Helping to change legislation to improve access
- Personal journey of CAR-T treatment

4.45 Chairman's Closing Remarks

5.15 Close of Annual CAR-TCR Summit Asia

Pre-Conference Workshop Day Tuesday 18th June 2019

Workshop A

Challenges and Prospects of Allogeneic CAR-T Cell Therapy

9:00am – 12:00pm

Whilst most success in CAR-T therapies is currently seen in the autologous space we are seeing a drive for progress in allogeneic CAR-T therapies.

Join us as we discuss:

- Desgin for allo-CAR-T
- Safety issue for Allo-CAR-T
- GVHD/HVGD
- Allo-CAR-T and its manufacture
- Features and applications of uCAR-T and HLA-half matched donor CAR-T of "Beijing Approach"

Zhongwei Xu
CSO
Bioceltech Therapeutics

- 1991, Suicide Gene Therapy Using Retroviral Vector Induced "HSV-TK/GCV" System on Gastric Cancer, Peking University, China
- 1993, LAK Cell Therapy for Advanved Cancer Patients, PI, Beijing, China
- 1996, anti-CEA CAR-T Therapy for Gastric Cancer, Visiting Scholar, Fukuoka University, Japan,
- 2005, anti-CD19 CAR-T Therapy, Project Manger, Carl June' s Group, University of Pennsyvania, USA
- 2016, Allo-CAR-T "Beijing Approach" for ALL, CSO, Beijing, China
- 2017, Auto/Allo-CAR-T Therapy, Chair and CSO, Bioceltech Therapeutics, Ltd, Beijing, China
- Visiting Professor, Dept. of Immunology, Peking Univesity,
- Distinguished Professor, Capital Medical University, China

Workshop B

Setting up and Managing Clinical Trials across Multiple Countries: The CRO Perspective

1.00pm – 4.00pm

In the race to globalize CAR-TCR therapies there is a need to understand the varying global requirements needed to run effective trials.

Join us as we discuss:

- How to run a clinical program
- What are the different standards of care across the globe
- Effective delivery of products
- Establishing appropriate primary endpoints for engineered T cell trials
- Taking into account patient population used in study
- Patient identification and stratification
- Biomarkers of response
- Regualtory requirements for IND submission

Martin Lachs
VP, Global Project Management
ICON

With over 23 years' experience in clinical development, Martin has worked across a number of therapeutic areas whilst specialising in oncology. He has been based in the UK throughout his career.

Martin heads up ICON's Oncology and Hematology Project Management Group, lending operational and indication expertise across a group of nearly 50 international project management staff, dedicated to oncology drug development.

Partners

Lead Partner

Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our more than 25 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 1,800 employees in 25 countries.

www.miltenyibiotec.com

Expertise Partners

Program Partners

Hosting Partners

Exhibitors & Partners

BECOME A COMMERCIAL PARTNER

Jennifer Mackay and Jonathan Kilby-Phillips
Commercial Directors, CAR-TCR Series
Tel: +44 203 141 8700
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.cartcr-asia.com/register/

Tel: +44 (0)20 3141 8700

Email: register@hansonwade.com

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Pharma & Biotech CAR-T & TCR therapy Developer Pricing	Register & Pay by Friday 10th May, 2019	Standard Prices
Conference + 2 Workshops	$1997 **(save $100)**	$2097
Conference + 1 Workshop	$1598 **(save $100)**	$1698
Conference Only	$1199 **(save $100)**	$1299

Standard Pricing	Register & Pay by Friday 10th May, 2019	Standard Prices
Conference + 2 Workshops	$3697 **(save $100)**	$3797
Conference + 1 Workshop	$3098 **(save $100)**	$3198
Conference Only	$2499 **(save $100)**	$2,599

Academic & Hospital Pricing	Register & Pay by Friday 10th May, 2019	Standard Prices
Conference + 2 Workshops	$1527 **(save $100)**	$1627
Conference + 1 Workshop	$1228 **(save $100)**	$1328
Conference Only	$929 **(save $100)**	$1029

*10% WHT will be added if the company registering is a Chinese-based business





VENUE

Shanghai Marriott Pudong East
15 Xinjinqiao Road, Pudong New District,
Shanghai, 201206, China

For further information or assistance, please visit www.marriott.co.uk

Code: 11997